Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.
Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...
Nominees this week included students from Adams High and NorthWood High. Check back on Monday for next week's nominees!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback